Author

R. Versteeg

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Approach:statistical model· 2 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

J. Koster· 4 shared E. M. Westerhout· 2 shared J. van Nes· 2 shared A. Alchahin· 1 shared A. Chan· 1 shared A. Crespo· 1 shared A. Lakeman· 1 shared A. Louwagie· 1 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

J. Koster

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma

T. K. Olsen, C. Dyberg, B. Embaie, A. Alchahin, J. Milosevic, J. Otte, C. Tummler, I. H. Myrberg, E. M. Westerhout, J. Koster, R. Versteeg, P. Kogner, J. I. Johnsen, D. B. Sykes, N. Baryawno

This study identifies DHODH as a prognostic marker and therapeutic target in neuroblastoma, showing its inhibition improves survival in preclinical models and suggests combination therapy with temozolomide.

bioRxiv · Sep 25, 2021Cancer Biology

An immature subset of neuroblastoma cells synthesizes retinoic acid and depends on this metabolite

T. van Groningen, C. U. Niklasson, A. Chan, N. Akogul, E. M. Westerhout, K. von Stedingk, M. Hamdi, L. J. Valentijn, S. Mohlin, P. Stroeken, N. E. Hasselt, F. Haneveld, A. Lakeman, D. A. Zwijnenburg, P. van Sluis, , J. van Nes

The paper identifies an immature neuroblastoma subset that synthesizes retinoic acid and is resistant to it, potentially contributing to therapy-resistant relapses.

bioRxiv · May 18, 2021 · PreprintCancer Biology

Cell lineage as a predictor of immune response in neuroblastoma

S. Sengupta, S. Das, A. Crespo, B. Miller, B. Sharma, S. Zhang, R. Dries, H. Huang, M. Krajewska, D. N. Debruyne, L. Soriano, M. A. Cohen, R. Versteeg, R. Jaenisch, S. Spranger, , R. E. George

This study identifies cell lineage as a key determinant of immune response in neuroblastoma by analyzing transcriptional signatures from 498 tumors and showing that mesenchymal-like cells are more immunogenic than adrenergic neuron-like cells.

bioRxiv · Jan 29, 2021Cancer Biology

SOX11 is a lineage-dependency factor and master epigenetic regulator in neuroblastoma

B. Decaesteker, A. Louwagie, S. Loontiens, F. De Vloed, J. Roels, S. Vanhauwaert, S. De Brouwer, E. Sanders, G. Denecker, E. D'haene, S. Van Haver, W. Van Loocke, J. Van Dorpe, D. Creytens, N. Van Roy, , F. Speleman

This study identifies SOX11 as a critical transcription factor and epigenetic regulator in adrenergic neuroblastoma, showing its role in chromatin accessibility and cell identity.

bioRxiv · Aug 21, 2020 · PreprintCancer Biology

MEK inhibition causes Bim stabilization and sensitivity to Bcl2 family member inhibitors in RAS-MAPK mutated neuroblastoma

T. F. Eleveld, L. Vernooij, L. Schild, B. Koopmans, L. K. Alles, M. E. Ebus, P. G. van Sluis, H. N. Caron, J. Koster, R. Versteeg, E. M. Dolman, J. J. Molenaar

The paper identifies MEK inhibition combined with BCL2 family inhibitors as a potent treatment for RAS-MAPK mutated neuroblastoma by stabilizing Bim and increasing sensitivity to Bcl2 inhibitors.

bioRxiv · Feb 12, 2020 · PreprintCancer Biology